MedTrace Logo

Atrial Fibrillation in Relationship to Plasma Biomarkers

NCT04710745 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2021-01-15

No results posted yet for this study

Summary

The general objective of this study is to:

A. To identify novel plasmatic biomarkers associated with prevalent/incident atrial fibrillation in patients with high risk for AF and stroke.

B. To assess predictive ability of novel plasmatic biomarkers (especially apelin and miRNAs) on prevalent/incident atrial fibrillation in patients with high risk for AF and stroke.

C. To validate predictive models from previous studies based on comorbidities, age, sex, BMI, NT-proBNP, FGF-23, IGF-1 and IGFBP-1 on prevalent/incident AF in patients with high risk for AF and stroke.

Conditions

Interventions

DIAGNOSTIC_TEST

Peripheral blood samples for routine analysis including NT-proBNP and plasmatic biomarkers.

Sampling of peripheral venous blood for analysis of plasma concentration of plasmatic markers (Apelin, microRNA, FGF-23, IGF-1, IGFBP-1) and routine analysis (laboratory parameters: NT-proBNP, D-dimer, Creatinine Clearance, CRP, Hs-troponin).

DIAGNOSTIC_TEST

Echocardiography

ECHO parameters: * E/e´ * Mean e' septal and lateral wall * LA volume (Biplane Area-Length Method) * Left atrial volume index * Diameter of left atrium in PLAX * Severe aortic stenosis * Severe mitral regurgitation * Severe tricuspid regurgitation * Left ventricular end-diastolic diameter * Interventricular septum * Posterior wall * LV Mass * Left ventricular mass index

DIAGNOSTIC_TEST

ECG Holter monitor

Patient receives an ECG Holter for a 7-day monitoring.

DIAGNOSTIC_TEST

Standardized Mini-Mental Status Exam (SMMSE)

A screening test for evaluating cognitive performance of patients done in the clinician's office.

Sponsors & Collaborators

  • Premedix Academy

    lead OTHER

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-04
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Slovakia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04710745 on ClinicalTrials.gov